VNDA vs. GOSS, AKUS, VBIV, ANAB, ALBO, INVA, OPK, IRWD, LXRX, and XOMA
Should you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include Gossamer Bio (GOSS), Akouos (AKUS), VBI Vaccines (VBIV), AnaptysBio (ANAB), Albireo Pharma (ALBO), Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Lexicon Pharmaceuticals (LXRX), and XOMA (XOMA). These companies are all part of the "pharmaceutical preparations" industry.
Gossamer Bio (NASDAQ:GOSS) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.
81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 5.0% of Gossamer Bio shares are held by insiders. Comparatively, 7.7% of Vanda Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Gossamer Bio has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.
Vanda Pharmaceuticals received 389 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 68.55% of users gave Vanda Pharmaceuticals an outperform vote while only 65.32% of users gave Gossamer Bio an outperform vote.
In the previous week, Vanda Pharmaceuticals had 4 more articles in the media than Gossamer Bio. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 2 mentions for Gossamer Bio. Vanda Pharmaceuticals' average media sentiment score of 1.52 beat Gossamer Bio's score of 0.47 indicating that Gossamer Bio is being referred to more favorably in the media.
Gossamer Bio has a net margin of 0.00% compared to Gossamer Bio's net margin of -2.75%. Gossamer Bio's return on equity of -0.90% beat Vanda Pharmaceuticals' return on equity.
Vanda Pharmaceuticals has higher revenue and earnings than Gossamer Bio. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Gossamer Bio presently has a consensus price target of $7.65, suggesting a potential upside of 1,196.61%. Given Vanda Pharmaceuticals' higher possible upside, equities research analysts clearly believe Gossamer Bio is more favorable than Vanda Pharmaceuticals.
Summary
Vanda Pharmaceuticals beats Gossamer Bio on 10 of the 16 factors compared between the two stocks.
Get Vanda Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vanda Pharmaceuticals Competitors List
Related Companies and Tools
